Skip to main content
NewslettersWatchlist

Oncolytics Bio(ONC-T)
TSX

Today's Change
Real-Time Last Update
Day Low1.43
Day High1.46
Open:1.46
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Oncolytics Bio up on Monday (ONC)
BayStreet.ca
Biotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Cases
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
The Globe and Mail
Thursday’s analyst upgrades and downgrades
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
BayStreet.ca
Biotech Sector Advances in Pancreatic Cancer Research
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newsfile
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
Baystreet
Stocks in play: Oncolytics Biotech Inc
GlobeNewswire
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Newswire.ca
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Baystreet
Stocks in play: Oncolytics Biotech Inc.
Newswire.ca
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newsfile
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
BayStreet.ca
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates
Baystreet
Stocks in play: Oncolytics Biotech Inc
GlobeNewswire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Newswire.ca
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
BayStreet.ca
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer
BayStreet.ca
Innovative Strategies in the Fight Against Pancreatic Cancer: A 2023 Recap
Baystreet
Stocks in play: Oncolytics Biotech Inc.
GlobeNewswire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
Newswire.ca
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
BayStreet.ca
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer
Baystreet
Stocks in play: Oncolytics Biotech Inc.

Profile

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.